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EVPI was €1368 at a value of the ceiling ratio of €20,000. EVPPI
analysis showed that utilities had the largest contribution to the
overall EVPI. The partial EVPI for this subset of input parame-
ters was €517. Incorporating the newly collected data on utili-
ties into the model reduced the overall EVPI to €563 and the
partial EVPI for the utility input parameter to approximately €0.
CONCLUSIONS: Collecting additional information on utilities
strongly reduced the overall and partial EVPI. At the population
level, the value of collecting additional data on utilities out-
weighed the costs of data collection. Value of information analy-
sis proved to be useful to determine the parameters for which
additional data collection is most beneﬁcial.
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OBJECTIVES: There are currently no well-validated Patient
Reported Outcome (PRO) tools to measure dyspnea in COPD
patients that have been accepted for label claims. Guidelines for
measuring PROs to support label claims encourage patient input
to deﬁne endpoints for clinical trials. This study was designed to
understand COPD patients’ experience of dyspnea, and inform
strategy for measuring PRO endpoints in clinical trials.
METHODS: Seventy-eight individuals (55% male; mean age 58
years) with moderate to severe COPD (MRC grades III-V) across
6 countries participated in interviews/focus groups, describing
their breathing difﬁculties, severity, impacts and ﬂuctuations.
Themes were identiﬁed from a systematic content review of the
transcripts, and further reviewed by an additional 18 patients.
SESULTS: Six distinct sensations of dyspnea were reported, with
patients across multiple cultures demonstrating the ability to dif-
ferentiate between sensations. Patients reported a high level of
diurnal and day-to-day variation in both the nature and severity
of symptoms. A conceptual model was developed based on this
qualitative work and discussion with an expert panel of six clin-
icians and three psychometric experts. Patients conﬁrmed the
multi-sensational nature of dyspnea that is also suggested within
the literature—“a subjective experience of breathing discomfort
that consists of qualitatively distinctive sensations that vary in
intensity”. However, existing measures evaluate dyspnea as a
one-dimensional symptom (a single construct of shortness of
breath) with a broad recall period (one to two weeks). CON-
CLUSIONS: The model showed that a daily diary (with symp-
toms differentiated and assessed by patient-generated descriptive
language) is more relevant for evaluating patients’ experience of
dyspnea in clinical trials. This work demonstrates the value of
extensive, multi-cultural patient input during early stages of PRO
development to ensure that the endpoint strategy for supporting
labelling claims adequately ﬁts the conceptual model for the
patient experience of that condition.
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OBJECTIVES: Tiotropium is a once-daily inhaled anticholiner-
gic maintenance treatment with demonstrated effectiveness in
chronic obstructive pulmonary disease (COPD). We aimed to
compare persistence of tiotropium-use with other respiratory
drugs in COPD in current clinical practice. METHODS: The
PHARMO database includes, among others, drug-dispensing
and hospital discharge records for >2 million subjects in The
Netherlands. All probable COPD-patients were identiﬁed by new
respiratory drug use (age >54 yrs) or COPD-hospitalizations.
New users of tiotropium, ipratropium, long-acting beta-agonists
(LABAs), or ﬁxed combination of inhaled corticosteroids and
LABA (ICS&LABA), in 1998–2003, were included in the study.
Persistence was assessed quarterly during the ﬁrst year of follow-
up. Patients with a proportion of days covered (PDC) ≥80%
were considered persistent. Persistence was analysed using gen-
eralised estimating equations model. RESULTS: About 37% of
new users of tiotropium continued treatment for one year, com-
pared with 14% for ipratropium, 13% for LABA, and 17% for
ICS&LABA. Multivariate analyses showed that tiotropium-users
were 2–3 times more persistent with their therapy than patients
using ipratropium (relative risk [RR]: 2.0; 95% conﬁdence inter-
val [CI]: 1.8–2.3), LABA (RR: 2.9; 95%CI: 2.4–3.6), or
ICS&LABA (RR: 2.4; 95%CI: 2.1–2.8), respectively. Male
gender, age >70 years, pulmonologist as ﬁrst prescriber, prior 
use of other respiratory drugs, and previous hospitalization 
for COPD were all associated with enhanced persistence with 
the initial drug-therapy. CONCLUSIONS: Persistence with
tiotropium was increased compared to other respiratory drugs
in COPD in clinical practice. Additional research is required 
to understand the reasons for these higher persistence levels.
Enhanced treatment persistence may offer beneﬁts to both
patients and society in terms of decreased morbidity and costs.
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OBJECTIVES: Long-term patient adherence to treatment is the
key issue in the efﬁcacy of sublingual immunotherapy (SLIT). To
help clinicians to manage SLIT patients and improve their adher-
ence, a speciﬁc questionnaire: QUARTIS, has been developed
and validated. METHODS: Relevant concepts were identiﬁed
through a combination of literature research and clinician and
patient interviews. After comprehension tests with patients, two
pilot versions, one for patients beginning SLIT (QUARTIS-Start)
and one for patients undergoing SLIT (QUARTIS-Follow-up),
were drawn up and pilot tested in clinical practice. A cross-
sectional observational study including 191 adult patients with
allergic rhinitis beginning SLIT and 381 undergoing SLIT was
conducted to reduce the questionnaires, create their scoring 
and assess their psychometric properties. The ability of the
QUARTIS-Follow-up to predict patients’ intentions to complete
SLIT, motivations to continue the course of SLIT, and adherence
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assessed by the clinician was evaluated using areas under the
ROC curve. RESULTS: After item reduction and scoring,
QUARTIS-Start included 28 items grouped into 6 dimensions: 2
Disease Severity dimensions (Symptoms and Daily Allergy) and
4 Treatment Perception dimensions (Reasons for following
Immunotherapy, Advantages, Inconvenience, and Information).
QUARTIS-Follow-up included 27 items grouped into 7 dimen-
sions: 2 Disease Severity dimensions and 5 Treatment Perception
dimensions (Ease of Intake, Inconvenience, Satisfaction, Side-
Effects, and Continuation). Internal consistency was good (Cron-
bach’s alpha coefﬁcients: between 0.66 and 0.78). The predictive
values of the QUARTIS-Follow-up score for patients’ intentions,
patients’ motivations and patients’ adherence (evaluated by the
clinician) were respectively 0.826, 0.770, and 0.653. CON-
CLUSION: QUARTIS is the ﬁrst self-reported questionnaire
assessing patients’ perceptions of SLIT, before and during the
treatment. It demonstrates good predictive value and appears to
be a promising patient-management tool for use in clinical prac-
tice. Further psychometric and linguistic validation steps are
being conducted.
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OBJECTIVES: The Chronic Respiratory questionnaire—Self
Administered Standardized form (CRQ-SAS), a validated health
related quality of life instrument for patients with COPD, was
developed in U.S. and Canadian English to assess this impact.
Prior to use in an international study our team translated the
CRQ-SAS into 11 languages according to a rigorous protocol
ensuring conceptual equivalence and cultural relevance across
languages. METHODS: A specialist conducted the translation
process in each target country following an internationally rec-
ognized methodology: 1) two forward translations and their rec-
onciliation by native speakers of the target language and ﬂuent
in English; 2) backward translation by a native English speaker;
3) review by a clinician; and 4) comprehension test on ﬁve indi-
viduals with COPD. RESULTS: The process revealed two chal-
lenges: the translation of terms with a large semantic ﬁeld (e.g.
“upset”) and the translation of idiomatic expressions such as
“down in the dumps”. Together with the developers of the
instrument we found appropriate language versions to convey
the original concepts. CONCLUSION: We established 11 trans-
lations of the CRQ-SAS according to rigorous methodology. 
The availability of the CRQ-SAS in many languages facilitates
efforts to collect patient data across countries and enables
researchers to compare the impact of COPD on people’s lives
internationally.
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OBJECTIVES: To validate the Chronic Obstructive Pulmonary
Disease Severity Score (COPDSS), a severity screening tool spe-
ciﬁc to COPD patients, for use in the Spanish primary health
care system. METHODS: Cross-sectional, multicenter study,
which included clinically stable COPD patients, with a recent
spirometry, and a diagnosis of COPD based on a FEV1(%)
<80% predicted. All patients provided signed informed consent
to participate. Data on current respiratory symptoms and
number of COPD exacerbations in the previous 12 months were
collected, and patients were classiﬁed using the Medical Research
Council (MRC) dyspnea scale. The COPDSS was administered
by physicians in face-to-face interviews, and patients’ most
recent FEV1 values were recorded. Concurrent validity of the
COPDSS was evaluated by examining the association between
COPDSS scores and dyspnea status, number of exacerbations in
the last 12 months, and FEV1(%). Receiver Operating Charac-
teristics (ROC) curves were used to test the score’s sensitivity and
speciﬁcity. RESULTS: For this preliminary analysis, data was
available from a total of 292 predominantly male (86%) patients
(mean age = 67 years) reporting daily cough (71%), expectora-
tion (74%), progressive dyspnea (60%) having 2 exacerbations
per year as a mean. A moderate correlation was found between
FEV1(%) and COPDSS (r = −0.331, p < 0.001), though COPDSS
correlated more strongly with current dyspnea status (r = 0.595,
p < 0.001) and number of exacerbations in the past 12 months
(r = 0.510, p < 0.001). The instrument discriminated between
patients with varying degrees of dyspnea (grades 0, 1 or 2 vs
grades 3 or 4 on the MRC scale; area under the ROC curve =
0.867), and between patients deﬁned according to number of
exacerbations in the last 12 months (0–2 vs > = 3; area under
ROC curve = 0.787). CONCLUSIONS: This preliminary analy-
sis indicates that the COPDSS is likely to be a useful tool in
primary health care in Spain.
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OBJECTIVES: Existing pre-scored multi-attribute health status
classiﬁcation systems do not capture well the typical impairments
and ﬂuctuating nature of COPD. This study aimed to develop
COPD health proﬁles that describe the health status of these
patients over the course of one year and have these proﬁles
valued by the general population. METHODS: We developed 16
COPD health proﬁles. Each proﬁle combines a description of the
severity of COPD during the stable phase (in terms of symptoms,
impact on non-strenuous and strenuous activities, ability to
work, anxiety and depression, energy and tiredness) with a
description of the exacerbation proﬁle (in terms of frequency,
duration, severity of increase in respiratory and non-respiratory
symptoms, impact on daily activities, and response to treatment).
These proﬁles were valued by a representative sample of the
adult Dutch population using a Visual Analogue Scale (VAS) and
Time Trade Off (TTO). All respondents valued 10 COPD pro-
ﬁles during group sessions. Subsequently all respondents received
a questionnaire to value another 10 COPD proﬁles at home.
Respondents also valued 4 EQ-5D states. RESULTS: A total of
239 respondents attended the group sessions; 235 completed the
questionnaire. Both VAS and TTO values consistently decreased
as severity of COPD increased. When including all available
responses, mean VAS scores ranged from 0.84 (SD 0.12) for mild
COPD without exacerbations to 0.18 (SD 0.12) for very severe
COPD with one non-severe and one severe exacerbation per year.
Mean TTO values were signiﬁcantly higher and ranged from
0.98 (SD 0.09) to 0.43 (SD 0.27), respectively. Overall, within
each COPD severity stage, the utility decrement for exacerba-
